Global Congenital Heart Diseases Market Size, Status and Forecast 2019-2025

Published On: Jun 2019

Format: PDF

Publisher: QY Research

Pages: 91

Report ID: 1188

Congenital diseases are disorders in a newborn due to certain genetic factors (and sometimes in association with the environment) that often results in malformations or underdeveloped organs. Congenital Heart Diseases (CHD) results in malformed or undeveloped heart that presents in a newborn with breathing and circulation disorders. According to Lancet medical journal, CHD caused death of 0.22 million individuals and newborns globally in the year 2010. CHD was earlier erroneously associated with premature births, the association has no direct correlation with all forms of CHD and is mainly one of the many factors that can cause it. The genetic factors causing CHD consist of chromosomal errors in fertilization and the following meiotic division, these include: large chromosomal defects in trisomal chromosomes; small chromosomal defects like microdeletion of long/short arm of chromosome and random/environmentally induced mutation of heart muscle cell proteins, or associated proteins etc. The environmental factors like rubella infections, thalidomide drugs, metals (lithium, lead, mercury, etc), chronic illness in the mother (systemic lupus, diabetes, phenylketonuria, etc). Embryological changes, hormonal changes in the mother and certain birth deficiencies can also cause CHD and other birth defects in children. Besides these, according to some medical research reports, maternal obesity increased the chances of CHD in newborns; obesity was shown to increase the risk of previously hidden genetic traits of CHD in the new born children of such obese mothers.
The treatment of CHD varies from case to case; genetic testing/screening is mandatory in case the doctor suspects a genetic cause for the disease, in developed countries this is done for all newborns. The next step would be surgery or drug treatment, again this depends upon the severity of the condition. In most cases CHD presents itself as serious conditions with high risk of complications, hence surgery is the most followed procedure. In certain disorders like ASD a pediatric surgeon may ask the parents of a CHD child to wait for the child’s growth as ASD is known to disappear gradually, a surgery is performed if ASD persists after the child’s growth. Certain cases also require multiple surgeries and stenting in order to restore a malformed tract in the lungs, etc. Drugs like diuretics are given to regulate vasoconstriction that alleviates deoxygenation and helps remove toxins from the body, besides reducing the heartbeat.
In 2018, the global Congenital Heart Diseases market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Congenital Heart Diseases status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Congenital Heart Diseases development in United States, Europe and China.

The key players covered in this study
Pfizer
Abbott Laboratories
Eli Lilly
Ranbaxy Pharmaceutical
...

Market segment by Type, the product can be split into
Hypoplasia
Obstructive
Septal Defects

Market segment by Application, split into
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Congenital Heart Diseases status, future forecast, growth opportunity, key market and key players.
To present the Congenital Heart Diseases development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Congenital Heart Diseases are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Congenital Heart Diseases Market Size Growth Rate by Type (2014-2025)
1.4.2 Hypoplasia
1.4.3 Obstructive
1.4.4 Septal Defects
1.5 Market by Application
1.5.1 Global Congenital Heart Diseases Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Ambulatory Surgical Centers
1.5.4 Diagnostic Centers
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Congenital Heart Diseases Market Size
2.2 Congenital Heart Diseases Growth Trends by Regions
2.2.1 Congenital Heart Diseases Market Size by Regions (2014-2025)
2.2.2 Congenital Heart Diseases Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Congenital Heart Diseases Market Size by Manufacturers
3.1.1 Global Congenital Heart Diseases Revenue by Manufacturers (2014-2019)
3.1.2 Global Congenital Heart Diseases Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Congenital Heart Diseases Market Concentration Ratio (CR5 and HHI)
3.2 Congenital Heart Diseases Key Players Head office and Area Served
3.3 Key Players Congenital Heart Diseases Product/Solution/Service
3.4 Date of Enter into Congenital Heart Diseases Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Congenital Heart Diseases Market Size by Type (2014-2019)
4.2 Global Congenital Heart Diseases Market Size by Application (2014-2019)

5 United States
5.1 United States Congenital Heart Diseases Market Size (2014-2019)
5.2 Congenital Heart Diseases Key Players in United States
5.3 United States Congenital Heart Diseases Market Size by Type
5.4 United States Congenital Heart Diseases Market Size by Application

6 Europe
6.1 Europe Congenital Heart Diseases Market Size (2014-2019)
6.2 Congenital Heart Diseases Key Players in Europe
6.3 Europe Congenital Heart Diseases Market Size by Type
6.4 Europe Congenital Heart Diseases Market Size by Application

7 China
7.1 China Congenital Heart Diseases Market Size (2014-2019)
7.2 Congenital Heart Diseases Key Players in China
7.3 China Congenital Heart Diseases Market Size by Type
7.4 China Congenital Heart Diseases Market Size by Application

8 Japan
8.1 Japan Congenital Heart Diseases Market Size (2014-2019)
8.2 Congenital Heart Diseases Key Players in Japan
8.3 Japan Congenital Heart Diseases Market Size by Type
8.4 Japan Congenital Heart Diseases Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Congenital Heart Diseases Market Size (2014-2019)
9.2 Congenital Heart Diseases Key Players in Southeast Asia
9.3 Southeast Asia Congenital Heart Diseases Market Size by Type
9.4 Southeast Asia Congenital Heart Diseases Market Size by Application

10 India
10.1 India Congenital Heart Diseases Market Size (2014-2019)
10.2 Congenital Heart Diseases Key Players in India
10.3 India Congenital Heart Diseases Market Size by Type
10.4 India Congenital Heart Diseases Market Size by Application

11 Central & South America
11.1 Central & South America Congenital Heart Diseases Market Size (2014-2019)
11.2 Congenital Heart Diseases Key Players in Central & South America
11.3 Central & South America Congenital Heart Diseases Market Size by Type
11.4 Central & South America Congenital Heart Diseases Market Size by Application

12 International Players Profiles
12.1 Pfizer
12.1.1 Pfizer Company Details
12.1.2 Company Description and Business Overview
12.1.3 Congenital Heart Diseases Introduction
12.1.4 Pfizer Revenue in Congenital Heart Diseases Business (2014-2019)
12.1.5 Pfizer Recent Development
12.2 Abbott Laboratories
12.2.1 Abbott Laboratories Company Details
12.2.2 Company Description and Business Overview
12.2.3 Congenital Heart Diseases Introduction
12.2.4 Abbott Laboratories Revenue in Congenital Heart Diseases Business (2014-2019)
12.2.5 Abbott Laboratories Recent Development
12.3 Eli Lilly
12.3.1 Eli Lilly Company Details
12.3.2 Company Description and Business Overview
12.3.3 Congenital Heart Diseases Introduction
12.3.4 Eli Lilly Revenue in Congenital Heart Diseases Business (2014-2019)
12.3.5 Eli Lilly Recent Development
12.4 Ranbaxy Pharmaceutical
12.4.1 Ranbaxy Pharmaceutical Company Details
12.4.2 Company Description and Business Overview
12.4.3 Congenital Heart Diseases Introduction
12.4.4 Ranbaxy Pharmaceutical Revenue in Congenital Heart Diseases Business (2014-2019)
12.4.5 Ranbaxy Pharmaceutical Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details